Glucorticoid‐induced obesity individuals have distinct signatures of the gut microbiome

Qiu, Dongxu; Xia, Zhiwei; Deng, Jun; Xiao, Jiangjian; Liu, Lanzhi; Li, Jing

doi:10.1002/biof.1565

Cited by 38 publications

(35 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…and ) showed an overall increase in the relative abundance of Clostridiales and a decrease in Bacteroidales and Verruomicrobiales groups. Our changes are consistent with published studies that examined the microbiota following GC‐Tx in mice and more importantly similar changes were observed in GC‐Tx humans . The latter indicates the potential for translation of our findings to humans.…”

Section: Discussionsupporting

confidence: 92%

“…Our changes are consistent with published studies that examined the microbiota following GC-Tx in mice (31) and more importantly similar changes were observed in GC-Tx humans. (114) The latter indicates the potential for translation of our findings to humans. These studies are particularly interesting because different GC molecules were used (prednisolone, prednisone or dexamethasone), indicating that GC treatment in general may have a reliable effect on fecal bacterial groups and microbial dysbiosis.…”

Section: Discussionmentioning

confidence: 70%

See 1 more Smart Citation

Involvement of the Gut Microbiota and Barrier Function in Glucocorticoid-Induced Osteoporosis

Schepper

Collins

Rios‐Arce

et al. 2019

Journal of Bone and Mineral Research

133

119

View full text Add to dashboard Cite

Glucocorticoids (GCs) are potent immune‐modulating drugs with significant side effects, including glucocorticoid‐induced osteoporosis (GIO). GCs directly induce osteoblast and osteocyte apoptosis but also alter intestinal microbiota composition. Although the gut microbiota is known to contribute to the regulation of bone density, its role in GIO has never been examined. To test this, male C57/Bl6J mice were treated for 8 weeks with GC (prednisolone, GC‐Tx) in the presence or absence of broad‐spectrum antibiotic treatment (ABX) to deplete the microbiota. Long‐term ABX prevented GC‐Tx‐induced trabecular bone loss, showing the requirement of gut microbiota for GIO. Treatment of GC‐Tx mice with a probiotic (Lactobacillus reuteri [LR]) prevented trabecular bone loss. Microbiota analyses indicated that GC‐Tx changed the abundance of Verrucomicobiales and Bacteriodales phyla and random forest analyses indicated significant differences in abundance of Porphyromonadaceae and Clostridiales operational taxonomic units (OTUs) between groups. Furthermore, transplantation of GC‐Tx mouse fecal material into recipient naïve, untreated WT mice caused bone loss, supporting a functional role for microbiota in GIO. We also report that GC caused intestinal barrier breaks, as evidenced by increased serum endotoxin level (2.4‐fold), that were prevented by LR and ABX treatments. Enhancement of barrier function with a mucus supplement prevented both GC‐Tx–induced barrier leakage and trabecular GIO. In bone, treatment with ABX, LR or a mucus supplement reduced GC‐Tx–induced osteoblast and osteocyte apoptosis. GC‐Tx suppression of Wnt10b in bone was restored by the LR and high‐molecular‐weight polymer (MDY) treatments as well as microbiota depletion. Finally, we identified that bone‐specific Wnt10b overexpression prevented GIO. Taken together, our data highlight the previously unappreciated involvement of the gut microbiota and intestinal barrier function in trabecular GIO pathogenesis (including Wnt10b suppression and osteoblast and osteocyte apoptosis) and identify the gut as a novel therapeutic target for preventing GIO. © 2019 American Society for Bone and Mineral Research.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionmentioning

confidence: 70%

Involvement of the Gut Microbiota and Barrier Function in Glucocorticoid-Induced Osteoporosis

Schepper

Collins

Rios‐Arce

et al. 2019

Journal of Bone and Mineral Research

133

119

View full text Add to dashboard Cite

show abstract

“…Kim JW et al reported that the Firmicutes/Bacteroidetes ratio was consistently reduced in systemic lupus erythematosus (SLE) patients [23]. On the contrary, Qiu D et al reported that the bacterial communities of the glucocorticoidinduced obesity group of people were increased in Firmicutes and decreased in Bacteroidetes compared with the healthy controls [24]. Zhao L et al reported that the ratio of Firmicutes/Bacteroidetes was higher in type 2 diabetes (T2D) patients than the healthy controls [25].…”

Section: Discussionmentioning

confidence: 99%

Effects of Xiao-Ban-Xia-Tang Formula on Cisplatin and 1-phenylbiguanide Hydrochloride Induced Emesis and Gut Microbiota in the Pica Model of Rats

Yang¹,

Feng²,

Chen³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: In this study, the effects of Xiao-Ban-Xia-Tang (XBXT) formula on cisplatin and 1-phenylbiguanide hydrochloride (1-PBG) induced acute and delayed emesis and gut microbiota were studied in the pica model of rats, compared with ondansetron. Methods: Two rat models of cisplatin and 1-PBG induced pica were established, the amount of kaolin intake was observed, and the effects of XBXT and ondansetron on the gut microbiota were further studied by 16S rDNA gene analysis. Results: The results showed that the total intake of kaolin of the rats injected with cisplatin and 1-PBG was significantly increased, and treatment of XBXT and ondansetron could significantly ameliorate the acute and delayed pica induced by cisplatin and 1-PBG. The 16S rDNA gene analysis has shown that the alpha diversity of the gut microbiota of the cisplatin and 1-PBG treated rats was significantly decreased compared with the control group, and ondansetron could further decrease the alpha diversity of the gut microbiota of the rats treated with cisplatin. Ondansetron significantly decreased the relative abundance of Firmicutes and increased the abundance of Bacteroidetes on phylum level in the cisplatin and 1-PBG treated rats, while XBXT only decreased Firmicutes in the cisplatin treated rats. Conclusions: XBXT was as effective as ondansetron in the treatment of acute and delayed pica induced by cisplatin and 1-PBG in rats. Ondansetron was more likely to cause gut microbiota dysbiosis than XBXT. Our study provided new avenues for the roles and mechanisms of XBXT on the prevention and treatment of CINV.

show abstract

“…To this regard, two recent studies reported that glucocorticoids induce gut microbial alterations in mice. (Schepper et al, 2019) and humans (Qiu et al, 2019). In human subjects diagnosed for acute transverse myelitis, 3 months treatment with prednisone promoted enrichment in Firmicutes and depletion in Bacteroidetes (Qiu et al, 2019).…”

Section: Drugs Used To Treat Covid-19 and Microbiotamentioning

confidence: 99%

Gut Microbiota Status in COVID-19: An Unrecognized Player?

Zeppa

Agostini

Piccoli

et al. 2020

Front. Cell. Infect. Microbiol.

108

View full text Add to dashboard Cite

Infection with the SARS-CoV-2 virus causes cardiopulmonary and vascular complications, ranging in severity. Understanding the pathogenic mechanisms of the novel SARS-CoV2 infection and progression can provide potential novel targets for its prevention and/or treatment. Virus microbiota reciprocal interactions have been studied in a variety of viral infections. For example, the integrity of Coronavirus particles can be disrupted by surfactin, a bacterial surface molecule that targets other viruses, including that of influenza A. In this light, intestinal microbiota likely influences COVID-19 virulence, while from its side SARS-CoV-2 may affect the intestinal microbiome promoting dysbiosis and other deleterious consequences. Hence, the microbiota pre-existing health status and its alterations in the course of SARS-CoV-2 infection, are likely to play an important, still underscored role in determining individual susceptibility and resilience to COVID-19. Indeed, the vast majority of COVID-19 worst clinical conditions and fatalities develop in subjects with specific risk factors such as aging and the presence of one or more comorbidities, which are intriguingly characterized also by unhealthy microbiome status. Moreover, these comorbidities require complex pharmacological regimens known as “polypharmacy” that may further affect microbiota integrity and worsen the resilience to viral infections. This complex situation may represent a further and underestimated risk with regard to COVID-19 clinical burden for the elderly and comorbid people. Here, we discuss the possible biological, physiopathological, and clinical implications of gut microbiota in COVID-19 and the strategies to improve/maintain its healthy status as a simple and adjunctive strategy to reduce COVID-19 virulence and socio-sanitary burden.

show abstract

Glucorticoid‐induced obesity individuals have distinct signatures of the gut microbiome

Cited by 38 publications

References 33 publications

Involvement of the Gut Microbiota and Barrier Function in Glucocorticoid-Induced Osteoporosis

Involvement of the Gut Microbiota and Barrier Function in Glucocorticoid-Induced Osteoporosis

Effects of Xiao-Ban-Xia-Tang Formula on Cisplatin and 1-phenylbiguanide Hydrochloride Induced Emesis and Gut Microbiota in the Pica Model of Rats

Gut Microbiota Status in COVID-19: An Unrecognized Player?

Contact Info

Product

Resources

About